{"product_id":"phase-ii-clinical-development-of-new-drugs-practical-guide","title":"Phase II Clinical Development of New Drugs - Practical Guide","description":"\u003cp\u003eIn this review the book Phase II Clinical Development of New Drugs is presented as a focused resource for statisticians, clinical trial designers and project team members planning mid-stage trials. The bottom line: it is most valuable for readers who need practical guidance on how to design Phase II trials and analyze their data to improve the chance of success in Phase III. The review highlights how the text frames the entire drug development process and pinpoints common pitfalls, making it a useful reference during protocol development and internal project reviews.\u003c\/p\u003e\n\u003ch2\u003eKey Features\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eComprehensive overview:\u003c\/strong\u003e Explains the role of Phase II within the broader drug development process so teams can align objectives from exploratory to confirmatory stages.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTrial design guidance:\u003c\/strong\u003e Covers practical approaches to designing Phase II clinical trials, enabling informed choices about endpoints and randomization.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eData analysis focus:\u003c\/strong\u003e Provides methods for analyzing Phase II data to draw reliable inferences that support go\/no-go decisions for Phase III.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRisk awareness:\u003c\/strong\u003e Highlights common potential pitfalls in Phase II execution and offers tips to avoid them, which helps reduce wasted resources.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProject team utility:\u003c\/strong\u003e Addresses key questions project teams must answer to increase probability of regulatory success later in development.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eWho It's For\u003c\/h2\u003e\n\u003cp\u003eThis book is best suited for biostatisticians, clinical trial designers, medical writers and project leaders involved in Phase II planning who need a single reference that links design, analysis and developmental decision making. It is also useful for graduate students in \u003cstrong\u003ebiostatistics\u003c\/strong\u003e who want a practical lens on mid-stage drug development rather than purely theoretical texts.\u003c\/p\u003e\n\u003cp\u003eThose looking for step-by-step protocols for any specific therapeutic area or a handbook of regulatory submission templates may need additional sources; the book focuses on planning and analysis principles rather than therapy-specific operational checklists.\u003c\/p\u003e\n\u003ch2\u003ePros \u0026amp; Cons\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003ePros\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eConcise linkage of Phase II design choices to later Phase III considerations, helping teams define meaningful objectives.\u003c\/li\u003e\n\u003cli\u003ePractical analysis recommendations that aid interpretation of mid-stage results for go\/no-go decisions.\u003c\/li\u003e\n\u003cli\u003eClear discussion of common pitfalls with actionable tips to reduce errors in trial execution.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCons\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNot a therapy-specific operational manual, so readers will need supplementary resources for disease- or indication-level details.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eSpecifications\u003c\/h2\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eTitle\u003c\/td\u003e\n\u003ctd\u003ePhase II Clinical Development of New Drugs (ICSA Book Series in Statistics)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuthors\u003c\/td\u003e\n\u003ctd\u003eNaitee Ting, Ding-Geng Chen, Shuyen Ho, Joseph C. Cappelleri\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary focus\u003c\/td\u003e\n\u003ctd\u003ePlanning and design of Phase II clinical trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContent emphasis\u003c\/td\u003e\n\u003ctd\u003eTrial design, data analysis, and project team decision points\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntended audience\u003c\/td\u003e\n\u003ctd\u003eBiostatisticians, trial designers, project teams\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey benefit\u003c\/td\u003e\n\u003ctd\u003eReduces risk by identifying pitfalls and offering avoidance tips\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eOur Verdict\u003c\/h2\u003e\n\u003cp\u003ePhase II Clinical Development of New Drugs is a pragmatic, focused reference for professionals who must design and analyze mid-stage trials with an eye toward successful Phase III outcomes. Its value lies in the clear connection between design choices and later regulatory goals, making it a worthwhile purchase for biostatistics teams and development leads who want to improve decision quality without wading through purely theoretical material.\u003c\/p\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eDoes this book cover statistical methods for Phase II analysis?\u003c\/strong\u003e\u003cbr\u003eThe book includes practical guidance on analyzing Phase II data and interpreting results to support go\/no-go decisions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIs it suitable for nonstatisticians on a project team?\u003c\/strong\u003e\u003cbr\u003eYes; project leaders and clinical planners will find the sections on team questions and pitfalls helpful, though some statistical familiarity is useful.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWill it replace therapy-specific guidance?\u003c\/strong\u003e\u003cbr\u003eNo; it complements therapy-specific and operational manuals but does not provide detailed disease-level protocols.\u003c\/p\u003e","brand":"Naitee Ting, Ding-Geng Chen, Shuyen Ho, Joseph C. Cappelleri","offers":[{"title":"Default Title","offer_id":48662647800027,"sku":"9811350744","price":122.28,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0724\/1043\/1707\/files\/61s1gmj3WyL._SL1254.jpg?v=1778690631","url":"https:\/\/gearmusthave.com\/products\/phase-ii-clinical-development-of-new-drugs-practical-guide","provider":"GearMustHave","version":"1.0","type":"link"}